Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

Lynn Connolly, M.D., Ph.D., Chief Medical Officer of Adagio Therapeutics, Inc. (the "Company"), has resigned her position, effective as of March 25, 2022, to tend to family obligations. Dr. Connolly will continue to serve as Chief Medical Officer through the Company's previously announced analysis of the ADG20 clinical data from its global Phase 2/3 clinical trials for the prevention and treatment of COVID-19 to assess the preliminary safety and efficacy of ADG20 at the 300mg dose in each trial and to transition her responsibilities. Ellie Hershberger, PharmD, the Company's Chief Development Officer, will assume responsibility for the Company's clinical development programs on a permanent basis. The Company expects to enter into a consulting agreement with Dr. Connolly. The Company and its Board of Directors thank Dr. Connolly for her contributions and wish her well in her future endeavors.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses